OP 2.3 – 00117 The EZH2 inhibitor Tazemetostat increases MHC I antigen presentation in vitro and in vivo, enhancing antiviral activities of HIV-specific CTLs
A. Gramatica,
A. Danesh,
I. Miller,
J. Weiler,
F. Khan,
D. Copertino,
U. Chukwukere,
L. Leyre,
B. Jones
Affiliations
A. Gramatica
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA
A. Danesh
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA
I. Miller
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA
J. Weiler
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA
F. Khan
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA
D. Copertino
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA
U. Chukwukere
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA
L. Leyre
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, USA
B. Jones
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, USA
